SCHEMBL190262

SCHEMBL190262

COCCNC1CCN(S(C)(=O)=O)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
TP53 P04637 1/20 0.47
FABP6 P51161 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
SMYD3 Q9H7B4 3/20 0.43
MAPT P10636 1/20 0.42
OPRL1 P41146 1/20 0.41
CYP3A4 P08684 1/20 0.40
GSK3B P49841 1/20 0.40
NAMPT P43490 1/20 0.39
HPGD P15428 1/20 0.39
CCNT1 O60563 1/20 0.38
CDK4 P11802 1/20 0.38
CCND1 P24385 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
CDK9 P50750 1/20 0.38
CDK6 Q00534 1/20 0.38
HPGDS O60760 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23634820 0.85 FABP6 (0.45) ALDH1A1TP53FABP6SMN1; SMN2SMYD3
SCHEMBL14400085 0.81 FABP6 (0.49) ALDH1A1TP53FABP6SMYD3OPRL1
SCHEMBL6976860 0.79 TP53 (0.41) ALDH1A1TP53FABP6SMN1; SMN2SMYD3
SCHEMBL12750868 0.77 FABP6 (0.51) ALDH1A1TP53FABP6SMN1; SMN2SMYD3
SCHEMBL190633 0.77 EHMT2 (0.40) ALDH1A1SMYD3MAPTOPRL1
SCHEMBL21779182 0.76 SMYD3 (0.41) ALDH1A1SMN1; SMN2SMYD3MAPTCYP3A4
SCHEMBL4761390 0.75
SCHEMBL24171160 0.75 KDM4E (0.37) ALDH1A1SMYD3MAPTNAMPT
SCHEMBL28203430 0.75 ALDH1A1 (0.36) ALDH1A1SMYD3MAPTNAMPTHPGD
SCHEMBL28203429 0.75 ALDH1A1 (0.43) ALDH1A1TP53SMN1; SMN2SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-04-21 US disclosed
US-20210317109-A1 TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND MEDSHINE DISCOVERY INC. (CN) 2021-10-14 US disclosed
EP-3848367-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) 2021-07-14 EP disclosed
US-9943519-B2 Pharmaceutical compounds GENENTECH, INC. (US) 2018-04-17 US disclosed
US-20160152632-A9 PHARMACEUTICAL COMPOUNDS PIRAMED LIMITED (GB) 2016-06-02 US disclosed
US-20140309216-A1 PHARMACEUTICAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2014-10-16 US disclosed
US-8802670-B2 Pharmaceutical compounds F. HOFFMANN-LA ROCHE AG (CH) 2014-08-12 US disclosed
EP-2402347-A1 Pharmaceutical compounds F. Hoffmann-La Roche AG (CH) 2012-01-04 EP disclosed
EP-2041139-B1 PHARMACEUTICAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2011-11-09 EP disclosed
EP-2041139-A2 PHARMACEUTICAL COMPOUNDS F.HOFFMANN-LA ROCHE AG (CH) 2009-04-01 EP disclosed
US-20080076758-A1 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors PIRAMED LIMITED (GB) 2008-03-27 US disclosed
WO-2007127175-A2 PHARMACEUTICAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119376-A1 TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS CRBN, CSNK2A1, CSNK2A2 ALDH1A1 4087/4885TP53 332/4885FABP6 2901/4885
US-20210317109-A1 TRICYCLIC SUBSTITUTED PIPERIDINE DIONE COMPOUND CRBN, CLNS1A, ADRM1 ALDH1A1 2347/4885TP53 397/4885FABP6 3773/4885
US-20080076758-A1 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors PIK3CA, PIK3CD, PIK3CB ALDH1A1 2268/4885TP53 315/4885FABP6 3609/4885
US-20140309216-A1 PHARMACEUTICAL COMPOUNDS PIK3CA, PIK3CD, AKT3 ALDH1A1 1974/4885TP53 344/4885FABP6 1203/4885
US-20160152632-A9 PHARMACEUTICAL COMPOUNDS PIK3CA, PIK3CD, AKT3 ALDH1A1 1974/4885TP53 344/4885FABP6 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.